21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kevin KalinskyWilliam E BarlowJulie R GralowFunda Meric-BernstamKathy S AlbainDaniel F HayesNancy U LinEdith A PerezLori J GoldsteinStephen K L ChiaSukhbinder Dhesy-ThindPriya RastogiEmilio AlbaSuzette DelalogeMiguel MartinCatherine M KellyManuel Ruiz-BorregoMiguel Gil-GilClaudia H Arce-SalinasEtienne G C BrainEun-Sook LeeJean-Yves PiergaBegoña BermejoManuel Ramos-VazquezKyung-Hae JungJean-Marc FerreroAnne F SchottSteven ShakPriyanka SharmaDanika L LewJieling MiaoDebasish TripathyLajos PusztaiGabriel N HortobagyiPublished in: The New England journal of medicine (2021)
Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease-free survival and distant relapse-free survival than those who received endocrine-only therapy, whereas postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy. (Funded by the National Cancer Institute and others; RxPONDER ClinicalTrials.gov number, NCT01272037.).